Amgen (AMGN) return on equity (ROE)

Return on equity · fiscal 2025
89.1%

Amgen (AMGN) earned a return on equity of 89.1% in fiscal 2025 (the year ended December 31, 2025). That is 19.5 percentage points higher than the 69.6% of fiscal 2024. Figures as of 17 Nov 2026, 22:30 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
89.1%
Change on fiscal 2024
+19.5 pts
Highest on record
179.0%fiscal 2022
Lowest on record
7.8%fiscal 2017
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Amgen return on equity (ROE), in more detail

Across the 19 fiscal years on record (2007–2025), the highest was 179.0% in fiscal 2022 and the lowest 7.8% in fiscal 2017. The fiscal 2025 figure is higher than in 89% of the 18 earlier fiscal years on record, whose median is 23.9%.

History · 19 fiscal years

Return on equity by fiscal year

Amgen return on equity (ROE), year by year

Amgen (AMGN) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202589.1% 19.5 pts up
202469.6% 38.2 pts down
2023107.8% 71.2 pts down
2022179.0% 91.0 pts up
202188.0% 10.8 pts up
202077.2% 3.9 pts down
201981.1% 13.9 pts up
201867.2% 59.3 pts up
20177.8% 18.0 pts down
201625.8% 1.1 pts up
201524.7% 4.7 pts up
201420.0% 3.0 pts down
201323.0% 0.2 pts up
201222.8% 3.4 pts up
201119.4% 0.0 pts
201019.3% 1.0 pts down
200920.3% 0.9 pts up
200819.4% 2.8 pts up
200716.6%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Amgen and comparable companies
CompanyReturn on equityFiscal year
Novartis NVS30.3%2025
AstraZeneca AZN21.0%2025
Thermo Fisher Scientific TMO12.6%2025
Amgen AMGN89.1%2025
Gilead Sciences GILD37.5%2025
Abbott Laboratories ABT12.5%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AMGN

Amgen, figure by figure

Amgen (AMGN) overview: price, valuation and scorecardAll health care companies by market value

Amgen return on equity (ROE): questions and answers

What is Amgen's return on equity?

Amgen (AMGN) earned a return on equity of 89.1% in fiscal 2025 (the year ended December 31, 2025). That is 19.5 percentage points higher than the 69.6% of fiscal 2024.

Is Amgen's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 89% of the 18 earlier fiscal years on record, whose median is 23.9%.

What are the highest and lowest return on equity figures on record for Amgen?

Across the 19 fiscal years on record (2007–2025), the highest was 179.0% in fiscal 2022 and the lowest 7.8% in fiscal 2017.

How is Amgen's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Amgen (AMGN) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/AMGN/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.